NEW YORK (GenomeWeb News) – Healthcare technology services provider Clarient announced after the close of the market Monday that it will acquire the Huntsville, Ala.-based cancer molecular diagnostics company Applied Genomics.

The all-stock merger is valued at up to $17.6 million, "if all conditions and milestones set forth in the merger agreement are successfully met." Applied Genomics will become a wholly-owned subsidiary of Clarient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.